How do we implement ANNEXXa-I into our Clinical Practice?

November 30, 2023
For acute care physicians, anticoagulated patients presenting with intracranial hemorrhage (ICH) is an incredibly challenging clinical scenario. ANNEXa-I is a randomized, controlled, clinical trial which provides clinicians with important information on appropriate reversal of anticoagualtion to optimally care for these patients.
0 Comments

Real World Evidence for Management of Severe Bleeding in the Anticoagulated Patient: Impact of Specific Reversal Therapy for Intracranial Hemorrhage and Gastrointestinal Bleeding

July 28, 2023

Real World studies can provide the foundational support necessary for clinicians to effectively manage anticoagulated patients with severe, often life-threatening intracranial and gastrointestinal bleeding. While randomized controlled clinical trials have provided the initial data necessary for appropriate use of reversal agents such as andexanet alfa for Factor Xa associated bleeding, broader studies enrolling thousands of patients, many with significant co-morbidities, are extremely valuable to clinicians. New information regarding the randomized controlled trial ANEXXA-I, which was halted due to andexanet alfa efficacy, provides additional information supporting reversal therapy for severe bleeding.

0 Comments

The Role of Real World Evidence in Driving Clinical Care for Anticoagulated Patients with Life-Threatening Bleeding

March 31, 2023
Experts in Emergency Medicine, Pharmacy, and Neurocritical Care describe the impact of real world evidence on the care of life-threatening bleeding in the anticoagulated patient. While clinical trial data remain the standard for clinicians, real world data provide important additional information on the use of a particular Repletion or Reversal therapy for these patients.
1 Comments

What Are the Barriers to Success When Implementing Care Pathways for ICH Patients?

July 12, 2022

ICH remains deadly and pathways matter but they aren't always what we need and barriers can be overcome with knowledge.

0 Comments

How Do We Coordinate Care Within Our Hospitals To Improve Outcomes in Hemorrhagic Stroke Patients?

July 5, 2022
Coordinating the necessary care for hemorrhagic patients is complicated- learn the ropes from experts on the UC Stroke Team. "Smoother, faster better" is the name of the game.
0 Comments
RSS
123578910Last
Categories
More Entries

Aug 3

What Is the Clinical Impact of the Genetic Polymorphism Observed with the Effectiveness of some P2Y12 Inhibitors?

Haemin Go posted on 8/3/2021

Moderator:W. Brian Gibler, MD FACEP, FACC, FAHA
Other Participants: Deepak L. Bhatt, MD, MPH and Natalie Kreitzer, MD, MS

Role of genetic polymorphism in TIA and stroke is and has been controversial, since the initial introduction of clopidogrel. Hear Drs. Bhatt and Kreitzer discuss the basics and background associated with the metabolism of the various agents, where we have come, the management of ACSand also for acute ischemic stroke, the role of dual antiplatelet therapy (DAPT), pivotal trials such as THALES, PIVOT, and THEMIS, and the importance of closely monitoring for a recurrent stroke, which happens with high frequency within the 1st month post a stroke.

0 Comments
Please login or register to post comments.